Navigation Links
Research in fish provides new clues about deadly form of liver cancer
Date:7/4/2011

Hepatocellular carcinoma (HCC), the most common type of liver cancer, is a leading cause of cancer-related deaths worldwide. Although there are several treatment options available, they are largely unsuccessful because the disease is so poorly understood. Clinical studies of patients with HCC, combined with studies using mice and other animal models, have provided some clues, but many questions about how to diagnose and treat this deadly form of cancer remain. Zhiyuan Gong and Serguei Parinov from the National University of Singapore decided to pursue these questions using zebrafish as a model system. Their study uncovers new information that might help to diagnose and treat HCC in humans, and shows that zebrafish are a powerful and cost-effective model to study liver cancer. Gong and Parinov publish their results in Disease Models & Mechanisms on July 5th, 2011 at http://dmm.biologists.org/.

Previous work indicated that cancer cells from patients with HCC always have abnormally high activation of a cellular pathway called Ras. However, whether and how the Ras pathway actually causes liver cancer was not clear. To focus in on this issue, Gong and Parinov generated zebrafish that are genetically engineered to express a cancer-causing form of Ras (krasV12) in the liver. Fish that had the highest expression of krasV12 all died rapidly of malignant liver cancer (mostly within 30 days), whereas fish with lower krasV12 expression survived for longer and did not develop full-blown liver cancer. These results suggest that only very high levels of Ras pathway activation can cause HCC.

The researchers also uncovered abnormalities in several other cellular pathways in zebrafish that developed liver cancer, and genetic studies confirmed that the progression of disease happens similarly in zebrafish and humans. This allowed the researchers to establish a 'genetic signature' for HCC, which could potentially be translated into a method for diagnosing the disease in humans. In addition, the stage of cancer is an important factor in determining how patients should be treated. In this study, the researchers determined genetic signatures that were specific to early- and late-stage liver cancer, which might help in planning treatment regimes for patients with HCC.

These new findings using a zebrafish model of HCC should help to guide studies of this complex cancer in humans. Although validation studies in patients with HCC are required, this work provides new evidence that drugs targeting the Ras pathway are a promising avenue for therapy.


'/>"/>

Contact: Sarah Allan
sarah.allan@biologists.com
44-752-876-8387
The Company of Biologists
Source:Eurekalert

Related medicine news :

1. Health providers should emphasize breast cancer screening, Wayne State University research finds
2. Leeds researchers test benefit of fish oil in bowel cancer spread
3. Research examines dentists role in painkiller abuse
4. Research reveals new secret weapon for Le Tour
5. The Samuel Waxman Cancer Research Foundation awards more than $3.1 million in grants
6. Georgetown research identifies key reasons racial disparities exist in emergent stroke treatment
7. Group-Think Can Influence Your Memory, Research Shows
8. Journal of Dental Research increases its scientific impact factor
9. AOSSM presents prestigious research awards at annual meeting
10. Fox Chase researchers identify new mechanism used by cells to reverse silenced genes
11. BUSM researchers find herbal medicine treatment reduces inflammation in allergen-induced asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... D.C. (PRWEB) , ... March 23, 2017 , ... ... (LEAD Coalition) stands with all Americans facing life-altering and fatal diseases in opposition ... budget makes shortsighted decisions that would eviscerate care, services, and hope for the ...
(Date:3/23/2017)... ... , ... The Boulevard is honored to host Shriners and Masons Children’s Day ... in the Main West Entrance of The Boulevard (in front of JCPenney). , ... and each child with a parent or guardian will be photographed for free and ...
(Date:3/23/2017)... ... 23, 2017 , ... “Wounded Woman Be Ye Healed-Passing On A Legacy”: a ... Legacy” is the creation of published author, Desiree M Webb, a registered nurse, minister ... has been happily married to her husband, Paul, for over twenty-nine years. Desiree ...
(Date:3/23/2017)... ... March 23, 2017 , ... “The Trainer”: an electrifying ... author, Scotty, a fiction writer with an active imagination and an enthusiasm for action ... follows the tale of Wild Bill Hart, who sat looking at the thirty-three notches ...
(Date:3/22/2017)... ... March 22, 2017 , ... Cosmetic Town, ... first issue of its companion print magazine. The new magazine, scheduled for release ... to information provided by board-certified doctors from across the country. , According to ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
(Date:3/23/2017)... 23, 2017 /PRNewswire/ - Medicure Inc. ("Medicure" or ... pharmaceutical company, is pleased to announce that its ... from the U.S. Food and Drug Administration (FDA) ... for tetrabenazine tablets in the 12.5 mg and ... a generic equivalent of the branded product Xenazine ...
(Date:3/23/2017)... , March 23, 2017   Casetabs , the ... native mobile app for the iPhone. With this new ... coordination and communication for physician offices, ambulatory surgery centers ... app offers iPhone users even faster, more reliable access ... it even easier to connect care teams so that ...
Breaking Medicine Technology: